Integrating various kinds of omics data aids analysis, generates biological insights, and advances diagnostics and therapeutics development.

The integration of Clinical Data Studio into ICON’s service offerings helps unlock the full potential of the Medidata Data Experience, merging information from both Medidata and non-Medidata ...

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting ...

Icon could fail to innovate and keep an edge over regional and global CRO competitors, especially as data and analytics play an increasing role in clinical development.

According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited ( ICLR 1.86 ...

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 ...

Icon PLC’s $12 billion deal to acquire a rival, PRA Health Sciences, would create a contract research powerhouse and expand the role of technology in clinical trials and drug development.

OMR AI Navigation Assistant empowers operational clinical study metrics with generative AI to provide industry-leading analytics to transform data into business insights.

ICON Public Limited Company (NASDAQ:ICLR) is a leading healthcare intelligence and clinical research organization innovating next-gen therapies for better patient outcomes.